Antibody Engineering & Therapeutics Europe- Sara Majocchi -
Cambridge Healthtech Institute's 7th Annual
Antibody Engineering & Therapeutics Europe
Engineering Next-Generation Biotherapeutics in Immuno-Oncology
Costimulatory CD28 Bispecific Antibodies for Conditional Targeting of CD28 in the Tumor Microenvironment
Tumor-targeted CD28 bispecific antibodies (bsAbs) enable T cells costimulation in a TAA-dependent manner. We generated an array of TAA-CD28 κλ bodies targeting different tumors that enhance the antitumor response induced by T cell engagers (TCE) via the induction of T cell proliferation and activation, increased cytokine secretion and boosted anti-tumoral cytotoxicity. In vitro and in vivo data highlighting how CD28 bsAbs synergize with TCEs will be presented.
📍 London, UK
📆 ThursdayJune 22nd, 2023
🕐 1:20 p.m
Hilton London Canary Wharf
S Quay Square, Marsh Wall, London E14 9SH, UK
